The Relationship Between Thyroid-Stimulating Hormone Levels and Outcomes From SELECT
Steven I. Sherman, MD, discusses the relationship between thyroid-stimulating hormone levels and outcomes from the phase III SELECT trial.
Clinical Pearls
Steven I. Sherman, MD, associate vice-provost for Clinical Research, professor and chair, Endocrine Neoplasia and Hormonal Disorders, MD Anderson Cancer Center, discusses the relationship between thyroid-stimulating hormone levels and outcomes from the phase III SELECT trial. The SELECT trial looked at lenvatinib versus placebo for the treatment of patients with relapsed/refractory differentiated thyroid cancer.
- One side effect of lenvatinib is that it alters the absorption of levothyroxine.
- It was anticipated that this effect would raise serum TSH levels. This could be significant because TSH can stimulate the growth of thyroid cancer.
- Though many patients developed increased TSH levels and needed increased dosing of thyroid hormone throughout the SELECT trial, the efficacy of lenvatinib was not affected.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Radical Prostatectomy Shows Less Genitourinary Toxicity in Localized Prostate Cancer
April 30th 2025A study of 47,387 patients found radical prostatectomy had the lowest long-term risk of severe genitourinary complications after localized prostate cancer treatment compared to combination therapies.
Read More
